Necitumumab (Portrazza) approved for the treatment of advanced squamous non-small cell lung cancer (NSCLC)

Last Updated on

November 28, 2015 – The American Food and Drug Administration (FDA) just approved Necitumumab (Portrazza) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

Necitumumab (Portrazza) is a monoclonal antibody that blocks activity of the epidermal growth factor receptor (EGFR), a protein commonly found on squamous NSCLC tutors. The efficacy of Necitumumab (Portrazza) was evaluated in a multicenter, randomized, open-label clinical study of 1,093 participants with advanced squamous NSCLC who received the chemotherapies gemcitabine and cisplatin with or without Necitumumab (Portrazza). Those taking Necitumumab (Portrazza) plus gemcitabine and cisplatin lived longer on average (11.5 months) compared to those only taking gemcitabine and cisplatin (9.9 months). Necitumumab (Portrazza) was not found to be an effective treatment in patients with non-squamous NSCLC.

Necitumumab (Portrazza) comes with some rather serious adverse effects though. The most common side effects of Necitumumab (Portrazza) are skin rash and magnesium deficiency (hypomagnesemia), which can cause muscular weakness, seizure, irregular heartbeats and can be fatal. Necitumumab (Portrazza) includes a Boxed Warning to alert health care providers of serious risks of treatment with Necitumumab (Portrazza), including cardiac arrest and sudden death, as well as hypomagnesemia.

Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015. The most common Lung Cancer Itype of lung cancer, non-small cell lung cancer, is further divided into two main types named for the kinds of cells found in the cancer – squamous cell and non-squamous cell (which also includes adenocarcinoma). “Since lung cancer tumors can be varied, treatment options need to be tailored to the specific type of lung cancer in the patient,” noted Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, and suggested that the approval of Necitumumab (Portrazza) provides certain patients with squamous cell lung cancer a new option that may extend survival.

However, the author of this blog likes to mention that seemingly the survival benefit of the combination of Necitumumab (Portrazza) and chemotherapy versus chemotherapy alone is incremental at best (see above, 9.9 months versus 11.5 months). Given the serious adverse effects profile of Necitumumab (Portrazza), the risk/benefit analysis of a treatment with Necitumumab (Portrazza) will not be easy for some patients and their treating physicians.

See and listen to the opinion of experts in oncology on Necitumumab (Portrazza):

 

Tags: , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login




avatar
  Subscribe  
Notify of

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Descendants of early Europeans and Africans in US carry Native American genetic legacy September 19, 2019
    Many people in the U.S. do not belong to Native American communities but still carry bits of Native American DNA, inherited from European and African ancestors who had children with indigenous individuals during colonization and settlement. In a new study published 19th September in PLOS Genetics, Andrew Conley of the Georgia Institute of Technology and […]
  • IGF1 gene is essential to adult tendon growth, animal study shows September 19, 2019
    Tendon injuries are among the most common injuries seen in athletes at all levels, from weekend warriors to professional basketball players. For those who rupture their tendons, returning to the same level of physical activity they enjoyed before the injury is rare.
  • Researchers create new protocol to improve gene therapy tool production September 19, 2019
    A method to create a faster and lower cost alternative for a gene therapy tool has been developed by Boston University School of Medicine (BUSM) researchers.
  • Genetic variants with possible positive implications for lifestyle September 19, 2019
    A German and British research team lead by Technical University of Munich (TUM) has examined the interplay between genetics, cardiovascular disease and educational attainment in a major population study. Genetic variants which had been linked to educational attainment in other studies were observed in the subjects. The researchers found that these variants also had implications […]
  • Scientists develop new methodology to genetically modify lab mice and human cells September 19, 2019
    A team led by Cedars-Sinai has designed a rapid method to genetically alter laboratory mice and then used this method to produce personalized animal models of pediatric glioma, an aggressive type of malignant brain cancer in children.
Top